TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: A potential novel approach to the treatment of metastatic colorectal cancer

It is now widely accepted that therapeutic antibodies targeting epidermal growth factor receptor (EGFR) can have efficacy in KRAS wild-type advanced colorectal cancer (CRC) patients. What remains to be ascertained is whether a subgroup of KRAS-mutated CRC patients might not also derive benefit from...

Descripción completa

Detalles Bibliográficos
Autores principales: Tarpgaard, Line S., Ørum-Madsen, Maj Sofie, Christensen, Ib J., Nordgaard, Cathrine, Noer, Julie, Guren, Tormod K., Glimelius, Bengt, Sorbye, Halfdan, Ikdahl, Tone, Kure, Elin H., Tveit, Kjell M., Nielsen, Hans J., Pfeiffer, Per, Brünner, Nils, Moreira, José M. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312323/
https://www.ncbi.nlm.nih.gov/pubmed/27509063
http://dx.doi.org/10.18632/oncotarget.11118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312323/
https://www.ncbi.nlm.nih.gov/pubmed/27509063
http://dx.doi.org/10.18632/oncotarget.11118

Ejemplares similares